Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Drotrecogin alpha (activated)

Nature Reviews Drug Discovery volume 2, pages 13–14 (2003)Cite this article

Abstract

In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet fulfilled these expectations. How has this situation arisen, and how might it develop?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Proposed actions of activated protein C.
Figure 2

References

  1. Bone, R. C., Grodzin, R. J. & Balk, R. A. Sepsis: a new hypothesis for the pathogenesis of the disease process. Chest 112, 235–243 (1997).

    Article  CAS  Google Scholar 

  2. Bernard, G. R. et al. Efficacy and safety of activated protein C for the treatment of severe sepsis. N. Engl. J. Med. 344, 699–709 (2001).

    Article  CAS  Google Scholar 

  3. Knaus, W. A. et al. APACHE II: a severity of disease classification system. Crit. Care Med. 13, 818–829 (1985).

    Article  CAS  Google Scholar 

  4. FDA Product Approval Information [online] (cited 1 Dec 2002) http://www.fda.gov/cber/label/droteli112101LB.pdf

  5. Angus, D. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303–1310 (2001).

    Article  CAS  Google Scholar 

  6. Angus, D. et al. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. American College of Chest Physicians Annual Meeting Abstract S144 (2002).

Download references

Author information

Authors and Affiliations

  1. Decision Resources, Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    John Lebbos, Julia Bradsher & Peter Kirkpatrick

Authors
  1. John Lebbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Bradsher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Lebbos.

Additional information

Peter Kirkpatrick is Associate Editor for Nature Reviews Drug Discovery. John Lebbos and Julia Bradsher

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lebbos, J., Bradsher, J. & Kirkpatrick, P. Drotrecogin alpha (activated). Nat Rev Drug Discov 2, 13–14 (2003). https://doi.org/10.1038/nrd991

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd991

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing